Precirix presents preclinical data of its FAP-targeting compound at the SNMMI annual meeting
Brussels, Belgium, 10 June 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, will present preclinical data of its FAP-targeting single domain antibody (sdAb) linked to multiple isotopes at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 annual meeting, 11-14 June in Vancouver, BC.
Precirix generated a sdAb with picomolar affinity for FAP (CAM-FAP), a target of strong interest in the radiopharmaceutical field due to its high expression on tumor-associated fibroblasts of epithelial derived cancers and limited expression in healthy adult tissue. At the SNMMI conference, Precirix will present the assessment of therapeutic efficacy of CAM-FAP after radiolabeling with the beta particle emitter Iodine-131 and the alpha particle emitter Actinium-225. Both CAM-FAP-I-131 and CAM-FAP-Ac-225 demonstrate high and sustained tumor targeting in vivo, translating into dose-dependent therapeutic efficacy in FAP-expressing tumor xenografted mice. The study confirms the potential of radiolabeled CAM-FAP for targeted radiotherapy in FAP-expressing cancers and warrants its clinical translation.
CAM-H2, Precirix’ lead compound, is currently in Phase I/II clinical development for the treatment of HER2- positive metastatic cancer. CAM-FAP will be the company’s second product candidate to enter clinical phase. Precirix plans to submit an IND by YE2022 and to initiate clinical trials in 2023.
Presentation details
Session SS43: New Probes Targeting Proteins & Receptors for Oncologic Applications:
2457 - Preclinical endoradiotherapy using a radiolabeled single-domain antibody targeting Fibroblast Activation Protein (June 14, 4pm PDT)
About Precirix
Precirix is a private, clinical-stage biopharmaceutical company founded in 2014 as a spin-off from the VUB, dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment. Precirix received grant funding from Innoviris Brussels to support this research.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.